首页> 外文期刊>Journal of pediatric hematology/oncology: Official journal of the American Society of Pediatric Hematology/Oncology >Refractory kaposiform hemangioendothelioma that expressed vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3: a case report.
【24h】

Refractory kaposiform hemangioendothelioma that expressed vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3: a case report.

机译:表达血管内皮生长因子受体(VEGFR)-2和VEGFR-3的难治性kaposiform血管内皮瘤:病例报告。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

This report describes the case of a 10-month-old boy who was diagnosed to have kaposiform hemangioendothelioma (KHE) with Kasabach-Merritt syndrome (KMS), which is a rare pediatric vascular tumor with a high mortality rate. Although both KHE with KMS were resistant to various therapies, such as oral prednisolone, sclerotherapy, and chemotherapy, repeated radiation therapy with methylprednisolone pulse therapy did reduce the volume of KHE and improved the symptoms of KMS. Unfortunately, a regrowth of KHE with KMS was observed 4 months after the cessation of treatment and the patient thereafter died from an intracranial hemorrhage and Pneumocystis carinii pneumonia, which is a complication related to repetitive radiation and steroid therapy. A histopathologic examination of autopsy specimens confirmed a diagnosis of KHE and immunohistologic staining was positive for vascular endothelial growth factor receptor (VEGFR)-2 and VEGFR-3. These findings may provide the rationale to further investigate the role of VEGFRs in the pathogenesis of KHE and also to elucidate its prognostic value, along with the application of inhibitors for VEGFRs for the treatment of refractory KHE.
机译:该报告描述了一个10个月大的男孩的案例,该男孩被诊断​​患有卡萨巴-梅里特综合征(KMS)的卡波西型血管内皮瘤(KHE),这是一种罕见的小儿血管肿瘤,死亡率很高。尽管两种KHE与KMS均对口服泼尼松龙,硬化疗法和化学疗法等多种疗法具有抵抗力,但甲基泼尼松龙脉冲疗法的反复放射疗法确实减少了KHE的体积并改善了KMS的症状。不幸的是,在停止治疗后4个月观察到KHE伴随KMS的再生,此后患者死于颅内出血和卡氏肺孢子虫肺炎,这是与重复放疗和类固醇疗法有关的并发症。尸检标本的组织病理学检查证实了KHE的诊断,并且免疫组织学染色对血管内皮生长因子受体(VEGFR)-2和VEGFR-3呈阳性。这些发现可能为进一步研究VEGFR在KHE发病机理中的作用,并阐明其预后价值,以及为抑制难治性KHE治疗应用VEGFR抑制剂提供了理论依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号